Growth and positioning of adipose-derived stem cells in microfluidic devices.
Wadhawan N., Kalkat H., Natarajan K., Ma X., Gajjeraman S., Nandagopal S.
Animal Study, published in Lab Chip (2012) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Lab Chip (2012)
- Country
- England
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 23007449
- DOI
- 10.1039/c2lc40891k
- Citations
- 11
Abstract (original English)
Stem cells hold great promise for treatment of various degenerative diseases. However, clinical studies have only shown very moderate benefits of cell therapy. We believe that insufficiency of therapeutic benefits is due to limited homing of implanted stem cells to targeted organs. Microfluidic devices are a very useful research tool for quantitative characterizations of stem cells. The present study therefore was to assess the effects of epidermal growth factor (EGF) and direct current electric field (dcEF) on the growth and trafficking of adipose-derived stem cells (ASC). It was found that EGF did not affect cell proliferation in cell-culture flasks. However, ASC proliferated at a higher rate in microfluidic devices with continuous infusion of EGF. Furthermore, we found that ASC migrated toward an EGF gradient in microfluidic devices. Moreover, we found that ASC tended to position perpendicularly to dcEF. The results suggest that EGF and dcEF may be effective in guiding homing and trafficking of implanted ASC.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.